Research Analysts’ Upgrades for October, 10th (FWONK, GAIA, GARS, GASS, GBDC, GIB, GNBC, GNMSF, GPMT, GSHD)

Research Analysts’ upgrades for Wednesday, October 10th:

Liberty Media Formula One Series C (NASDAQ:FWONK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $39.00 target price on the stock. According to Zacks, “Liberty Media Corporation owns interests in a broad range of media, communications and entertainment businesses through their operating subsidiaries and investments in various publicly-traded companies. The company broadcasts music, sports, entertainment, comedy, talk, news, traffic, and weather channels, as well as infotainment services on a subscription fee basis through its satellite radio systems; provides next-generation connected vehicle applications and services; streams music and non-music channels over the Internet; sells satellite and Internet radios to consumers through Website and retailers; and offers other ancillary services, such as weather, traffic, data, and Backseat television services. Liberty Media Corporation is headquartered in Englewood, Colorado. “

Gaia (NASDAQ:GAIA) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $18.00 target price on the stock. According to Zacks, “Gaia, Inc. provides digital video subscription service. Its video content is available through online digital streaming on virtually any Internet-connected device on a commercial-free basis. The Company’s subscribers access to a library of films, personal growth-related content, documentaries, interviews, yoga classes and fitness. It created a fitness and yoga-focused version of its video service. Gaia, Inc., formerly known as Gaiam Inc., is based in Louisville, United States. “



Garrison Capital (NASDAQ:GARS) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. Zacks Investment Research currently has $9.50 price target on the stock. According to Zacks, “Garrison Capital Inc. is an externally managed, closed-end, non-diversified management investment company. The Company’s investment objective is to generate current income and capital appreciation by making investments primarily in debt securities and loans of the United States-based middle-market companies, which it defines as those having annual earnings before interest, taxes and depreciation, or EBITDA of certain amount. It invests or provides direct lending in first lien senior secured loans, second lien senior secured loans, one-stop senior secured loans or unitranche loans, subordinated or mezzanine loans, unsecured consumer loans and to a lesser extent, selected equity co-investments in middle-market companies. The Company intends to generate risk-adjusted net returns by assembling a portfolio of investments. The Company’s investments include debt investments, preferred and minority equity investments (equity) of diversified companies and a portfolio of unsecured small balance consumer loans. “

StealthGas (NASDAQ:GASS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $3.75 target price on the stock. According to Zacks, “StealthGas Inc is a provider of international seaborne transportation services to LPG producers and users. The Company’s vessels carry various petroleum and petrochemical gas products in liquefied form, including propane, butane, butadiene, isopropane, propylene and vinyl chloride monomer, which are all byproducts of the production of oil and natural gas. These products are transported in liquefied form in order to reduce their volume and to facilitate their handling. Transportation by sea represents a major element of gas transportation logistics. LPG products have a variety of both industrial and other uses, including transportation, fertilizer production, the manufacture of plastics, space heating, cooking, water heating and process heating. We serve industrial companies, as well as national and independent energy companies and energy traders. “

Golub Capital BDC (NASDAQ:GBDC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $21.00 price target on the stock. According to Zacks, “Golub Capital BDC Inc. is a business development company that principally invests in senior secured, unitranche, mezzanine and second lien loans of middle-market companies that are, in most cases, sponsored by private equity investors. The Company’s investment activities are managed by its investment adviser, GC Advisors LLC, an affiliate of Golub Capital. “

CGI (NYSE:GIB) (TSE:GIB.A) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $70.00 target price on the stock. According to Zacks, “CGI provides the full range of IT services including consulting, systems integration and the management of business and IT functions. The company’s primary focus is large scale systems integration and outsourcing contracts. “

Green Bancorp (NASDAQ:GNBC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Green Bancorp, Inc. is a bank holding company for Green Bank, N.A. The Bank is a nationally chartered commercial bank providing commercial and private banking services. It offers deposit accounts comprising demand, savings, money market, and time accounts. The Company also provides loans, including residential real estate loans, home equity loans, home equity lines of credit, installment loans, unsecured and secured personal lines of credit, overdraft protection and letters of credit. It also provides a range of online banking solutions; and extended drive-through hours, and ATMs, as well as banking through telephone, mail, and personal appointment. Green Bancorp, Inc. is headquartered in Houston, Texas. “

Genmab A/S (OTCMKTS:GNMSF) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $170.00 target price on the stock. According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Granite Point Mortgage Trust (NYSE:GPMT) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Granite Point Mortgage Trust Inc. focuses primarily on directly originating, investing in and managing senior floating-rate commercial mortgage loans and other debt and debt-like commercial real estate investments. Granite Point Mortgage Trust Inc. is headquatered in New York, United States. “

Goosehead Insurance (NASDAQ:GSHD) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $33.00 target price on the stock. According to Zacks, “Goosehead Insurance Inc. operates as an insurance agency. Its product portfolio includes homeowner’s insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance, commercial lines insurance and life insurance. Goosehead Insurance Inc. is based in Texas, United States. “

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $168.00 price target on the stock. According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

Receive News & Ratings for Liberty Media Formula One Series C Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liberty Media Formula One Series C and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply